Cataya Bio
柯泰亚生物
Cataya Bio (柯泰亚生物) is a synthetic biology company that announced an oversubscribed Series A financing of over 100 million RMB in May 2022, led by Source Code Capital with participation from FoodXin Capital and Sherpa Healthcare Partners . Source Code Capital's Huang Yungang described synthetic biology as "a highly promising major direction" with the potential to significantly transform traditional petroleum-based chemical industries . The funding was earmarked for team expansion and platform development. elsewhere's corpus does not contain additional details on Cataya Bio's founding date, specific technology focus, or subsequent developments beyond this 2022 financing announcement.
AI-generated — may contain errors, please verify.
Coverage
Code Moment | Congratulations to METiS Pharmaceuticals on Its HKEX Listing, the World's First AI Drug Delivery Stock
Source Code Capital participated in METiS Pharmaceuticals' angel round in 2020 and continued to increase its stake in subsequent rounds.
MaKe | 12-inch Silicon Wafer Leader ESWIN Material Closes Nearly RMB 4 Billion Series C Round, Source Code Capital Joins
We look forward to supporting the long-term development of core Chinese technology enterprises like ESWIN Material.
Code Moment | "Senmu Leishi" Closes New Round of Tens of Millions of RMB, Existing Shareholder Source Code Capital Continues to Double Down
A leader in intelligent design upgrades for the power electronics industry
Code View | A Day in the Life of Green Power
Code Moment | Js.Design Announces Tens of Millions of Dollars in Series B+ Funding, Existing Shareholder Source Code Capital Follows On
Co-defining China's design tools with Chinese designers
Source Code Capital | "Coteya Bio" Announces Oversubscribed Series A Financing of Over 100 Million RMB, Led by Source Code Capital
Addressing a host of global challenges including environmental pollution, carbon emissions, and climate change
